To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Lapaquistat (TAK-475) is a cholesterol-lowering drug currently in phase 3 clinical trials. Unlike statins which inhibit HMG-CoA reductase, lapaquistat metabolits inhibit squalene synthase which is further downstream in the synthesis of cholesterol. It is hoped that side effects can be reduced by not disturbing the mevalonate pathway which is important for other biochemical molecules besides cholesterol.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lapaquistat". A list of authors is available in Wikipedia.|